This technology relates to a low-cost, high throughput microfluidic platform device which can help identify therapeutic compounds from a known agent, such as tuberculosis. Through a three-chip process, the invention can encapsulate, cultivate, screen and sort bacteria from a host of environmental microbes for bioactive natural products. The platform is disease agnostic, enabling a wide range of diagnostic capabilities, and provide equal if not better throughput than conventional liquid handling robots. Background: New paradigms and technological approaches enabling rapid and informed disease management need to be implemented. In this respect, disease diagnostics that use microfluidic systems for pathogen detection offers a host of innovative and promising solutions, such as this low-cost, high throughput disease agnostic microfluidic detection device. Applications:
Advantages: